Vanguard Group
VRNA

Vanguard Group’s Verona Pharma VRNA Stock Holding History

Vanguard Group’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-41,704
Closed -$426K – 4556
2022
Q3 		$426K Buy
+41,704
New +$351K ﹤0.01% 4257

Other funds holding VRNA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Vanguard Group's VRNA Position: Q4 2022 in Review

Vanguard Group sold out of Verona Pharma (VRNA) in Q4 2022, closing a stake of 41,704 shares — an estimated $426K sold.

Vanguard Group first reported a position in VRNA in Q3 2022 and held it in 1 quarter. The position peaked at $426K in Q3 2022. 88 funds tracked by Wall St. Rank hold VRNA as of Q4 2022.

  • Vanguard Group reported no remaining Verona Pharma position as of Q4 2022 after selling out during the quarter.
  • Vanguard Group sold 41,704 Verona Pharma shares in Q4 2022, an estimated $426K.
  • Vanguard Group first reported a position in Verona Pharma in Q3 2022 and held it in 1 quarter.
  • Vanguard Group's Verona Pharma position peaked at $426K in Q3 2022.
  • 88 funds tracked by Wall St. Rank held Verona Pharma as of Q4 2022.

Based on Vanguard Group's 13F filing for Q4 2022, filed 10 Feb 2023.